The Symposium will be held from 9 to12 March 2016 at the Athens Hilton in Athens, Greece
HALLE/SAALE, Germany, 09 March 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces today that Prof Dr Cynthia A. Lemere and Prof Dr Hans-Ulrich Demuth will be presenting at the 14th International Athens/Springfield Symposium on Advances in Alzheimer Therapy (AAT) in Athens, Greece.
Prof Dr Hans-Ulrich Demuth will hold a presentation entitled “The pyroglutamate modification of toxic A-beta resulted in new therapeutic approaches: Inhibitors of glutaminyl cyclase and highly specific antibodies – A status report” on Friday, 11 March 2016 in Room Hesperides at 8:50 am EET.
Hans-Ulrich Demuth co-founded Probiodrug and is a member of the company’s Scientific Advisory Board. He worked for several years as Chief Scientific Officer at Probiodrug on the molecular mechanisms of Alzheimer’s disease and laid the scientific ground for Probiodrug’s currently pursued targets. Hans-Ulrich Demuth is Head of the Department of Drug Design and Target Validation at the Fraunhofer Institute for Cell Therapy and Immunology IZI.
Prof Dr Cynthia Lemere’s presentation entitled “Phagocytic characterization and therapeutic efficacy of an Anti-PyroGlutamate-3 A-beta IgG2a antibody in aged APP/PS1dE9 mice” will be held on Saturday, 12 March 2016 in Room Terpsichore at 12:00 pm EET.
Cynthia Lemere is a Scientist at the Brigham and Women’s Hospital and Associate Professor of Neurology at the Harvard Medical School, Boston, USA. She is a member of the Scientific Advisory Board of Probiodrug and she and her team authored a number of papers describing the preclinical effects of Probiodrug’s anti-pGlu-Abeta Antibody as a result of an extended collaboration.
Inge Lues, Chief Development Officer of Probiodrug, stated: “We are extremely happy about our collaboration with Cynthia Lemere, who has applied her expertise in AD pathology to our programme and particularly her knowledge on the aspect of monoclonal Abeta antibody as therapeutic target.”
For more information, please contact:
Dr Konrad Glund, CEO
Mary Clark, Supriya Mathur, Alexia Faure
Tel: +44 (0) 20 7862 6475
Notes to Editors:
About Probiodrug AG
Headquartered in Halle, Germany, Probiodrug AG (Euronext Amsterdam: PBD) is a biopharmaceutical company focused on the development of new therapeutic products for the treatment of Alzheimer’s disease.
Founded in 1997, the company successfully developed a novel therapeutic concept for diabetes – the DP4 inhibitors – which provided the basis for a novel class of antidiabetics – the gliptins. Its core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes involved in the modification of proteins and peptides, which play a central role in pathological conditions.
Today Probiodrug’s aim is to become a leading company in the development of Alzheimer’s disease treatments and to thereby provide a better life for Alzheimer’s disease patients. It has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight Alzheimer’s disease. The Company has medical use and composition of matter patents related to the inhibition of Glutaminyl Cyclase (QC) and anti-pGlu-Abeta- specific monoclonal antibodies, providing it, in the Company’s view, with a leading position in this field of research.
About Alzheimer’s disease
Alzheimer’s disease is a neurological disorder, which is the most common form of dementia, and ultimately leads to death. Because Alzheimer’s disease cannot be cured and is degenerative, the affected patients must increasingly rely on others for assistance. Today, over 46 million people worldwide currently live with the condition and this number is expected to increase to 132 million by 2050. Alzheimer’s also has an estimated, global societal cost of US$ 818 billion (World Alzheimer Report 2015).
Forward Looking Statements
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Probiodrug AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.